Genentech’s ASCO 2026 data puts giredestrant at the centre of Roche’s breast cancer strategy
Endocrine therapy is crowded. Genentech needs giredestrant to prove it can shift breast cancer care, not just add another option.
Endocrine therapy is crowded. Genentech needs giredestrant to prove it can shift breast cancer care, not just add another option.